<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04286958</url>
  </required_header>
  <id_info>
    <org_study_id>HRHB-CE001</org_study_id>
    <nct_id>NCT04286958</nct_id>
  </id_info>
  <brief_title>A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC</brief_title>
  <acronym>ESCC</acronym>
  <official_title>A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Medical University Fourth Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess efficacy and safety of patients who receive
      camrelizumab as consolidation therapy after radical concurrent chemoradiotherapy in locally
      advanced ESCC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, 40 patients with locally advanced ESCC will be enrolled. All patients who had
      received radical concurrent chemoradiotherapy were treated with camrelizumab.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>evaluated in 24 months since the treatment began</time_frame>
    <description>Baseline to measured date of progression or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>tumor assessment every 6 weeks since the treatment began，up to 24 months</time_frame>
    <description>Baseline to measured stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durarion of response (DOR)</measure>
    <time_frame>tumor assessment every 6 weeks since the treatment began，up to 24 months</time_frame>
    <description>From the first assessment to CR or PR to the first assessment to PD or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>the first day of treatment to death or last survival confirm date,up to 24 months</time_frame>
    <description>Baseline to measured date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Toxicity according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. The number of Participants with adverse events will be recorded at each treatment visit</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biomarkers</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Relationship between tumor markers and efficacy in tumor tissues and peripheral blood (including but not limited to PD-L1, TMB, etc.)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Camrelizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients who had received radical concurrent chemoradiotherapy were treated with camrelizumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>Camrelizumab: 200 mg was given intravenously over a period of 30 minutes (no less than 20 minutes and no longer than 60 minutes)</description>
    <arm_group_label>Camrelizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age:18 to 75 years old;

          2. Histology confirmed as esophageal squamous cell carcinoma;

          3. T1bN+M0, T2-4N0-2M0 local progress period;

          4. Have previously received radical concurrent chemoradiotherapy;

          5. According to RECIST 1.1, at least one measurable lesion;

          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;

          7. Expected survival period ≥ 12 weeks;

          8. Major organ function has to meet the following certeria:

        1)For results of blood routine test HB≥90g/L; ANC≥1.5×109/L; PLT≥80×109/L; 2)For results of
        blood biochemical test ALB≥30g/L; ALT and AST&lt;2.5×ULN; TBIL≤1.5ULN; Serum creatinine
        ≤1.5ULN; 9. Left ventricular ejection fraction (LVEF) ≥50%; 10. Women of childbearing age
        must have contraceptive measures or have test pregnancy (serum or urine) enroll the study
        before 14 days, and the results must be negative, and take the methods of contraception
        during the test and the last to have drugs after 8 weeks. Men must be contraception or has
        sterilization surgery during the test and the last to have drugs after 8 weeks; 11.
        Participants were willing to join in this study, and written informed consent, good
        adherence, cooperate with the follow-up.

        Exclusion Criteria:

          1. Subjects with immunosuppressive medications within 14 days of first administration of
             study treatment, excluding nasal spray and inhaled corticosteroids or physiological
             doses of systemic steroid hormones (no more than 10 mg / day of prednisolone or other
             corticosteroids of equivalent pharmaceutical physiological dose);

          2. The patient has any active autoimmune disease or a history of autoimmune disease (such
             as the following, but not limited to: autoimmune hepatitis, interstitial pneumonia,
             uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis,
             Hyperthyroidism; patients with vitiligo; Asthma has been completely relieved in
             childhood, and patients who do not need any intervention after adulthood can be
             included; asthma patients who require bronchodilators for medical intervention cannot
             be included);

          3. Patients with other malignant tumors within 5 years (except for the treated skin basal
             cell carcinoma and cervical carcinoma in situ);

          4. Human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome
             (AIDS), active hepatitis B (HBV-DNA ≥1000 IU/ml) or hepatitis C (positive hepatitis C
             antibody, and HCV-RNA is higher than the lower limit of detection of the analytical
             method) or co-infection with hepatitis B and C, requiring antiviral treatment during
             the study ; 5.6 months before study drug administration, the following occurred:
             myocardial infarction, severe / unstable angina pectoris, grade III-IV cardiac
             insufficiency according to New York Heart Association(NYHA) criteria, uncontrolled
             arrhythmias (including QTcF interval male&gt; 450 ms, female&gt; 470 ms ,The QTcF interval
             is calculated using Fridericia formula), symptomatic congestive heart failure,
             cerebrovascular accidents (including transient ischemic attack or symptomatic
             pulmonary embolism);

        6.Severe infections within 4 weeks before study drug administration (eg. Need intravenous
        drip antibiotics, antifungals or antivirals) or Unexplained fever&gt;38.5℃ during screening
        visits or on the first scheduled day of dosing; 7.History of allogeneic organ
        transplantation or allogeneic hematopoietic stem cell transplantation; 8.Less than 4 weeks
        from the last clinical trial; 9.History of psychiatric drugs abuse and can't quit or
        patients with mental disorders; 10.The researchers think inappropriate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>JUN WANG, Ph.D</last_name>
    <phone>13931182128</phone>
    <email>wangjunzr@163.com</email>
  </overall_contact>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 25, 2020</study_first_submitted>
  <study_first_submitted_qc>February 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2020</study_first_posted>
  <last_update_submitted>February 25, 2020</last_update_submitted>
  <last_update_submitted_qc>February 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hebei Medical University Fourth Hospital</investigator_affiliation>
    <investigator_full_name>Jun wang</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

